Suzhou Zelgen Biopharmaceuticals Co., Ltd.
Shanghai Stock Exchange 688266.SS
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2023: USD 316.44 M
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Cash and Short-Term Investments is USD 316.44 M for the year ending December 31, 2023, a 108.77% change year over year. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
-
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2022 was USD 151.57 M, a -19.87% change year over year.
-
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2021 was USD 189.15 M, a -22.81% change year over year.
-
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2020 was USD 245.06 M, a 2,240.26% change year over year.
-
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Cash and Short-Term Investments for the year ending December 31, 2019 was USD 10.47 M, a -44.14% change year over year.
Key data
| Date | Cash and Short-Term Investments | Receivables | Inventory | Goodwill |
|---|
Market news
Loading...
Shanghai Stock Exchange: 688266.SS
| CEO | Mr. Zelin Sheng |
| IPO Date | Jan. 23, 2020 |
| Location | China |
| Headquarters | No. 209, Chenfeng Road |
| Employees | 867 |
| Sector | Health Care |
| Industries | |
Description
Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.
Key trends
Past 5 years
Similar companies
Asymchem Laboratories (Tianjin) Co., Ltd.
USD 10.09
5.71%
Zhejiang Orient Gene Biotech Co., Ltd.
USD 3.93
2.90%
StockViz Staff
January 15, 2025
Any question? Send us an email